Comparative Benefits of Primary Percutaneous Coronary Intervention Versus Onsite Fibrinolytic for Patients With ST-Segment-Elevation Myocardial Infarction: A Quasi-Experimental Study

J Am Heart Assoc. 2025 Jul;14(13):e041995. doi: 10.1161/JAHA.125.041995. Epub 2025 Jun 23.

Abstract

Background: Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy compared with onsite fibrinolytic therapy (O-FT) for ST-segment-elevation myocardial infarction when delivered promptly. However, the contemporaneous data to inform the comparative benefits of primary PCI versus O-FT, especially in developing countries, have been largely understudied.

Methods: We used data from the National Chest Pain Center Program (NCPCP), the largest nationwide registry in China, including patients with ST-segment-elevation myocardial infarction treated with primary PCI or O-FT from January 2016 to December 2022. Patients were matched using propensity scores, and the PCI-related delay was defined as the difference between the observed door-to-wiring time and the door-to-needle time. Mortality outcomes were assessed at different delay intervals (<60 minutes, 60-90 minutes, >90 minutes). Subgroup analyses were conducted based on age, infarction location, and Killip classification.

Results: In 19 334 matched patients, primary PCI demonstrated a significant mortality benefit over O-FT when PCI-related delays were <60 minutes (2.34% versus 6.01%). However, this advantage diminished when delays exceeded 90 minutes. The critical threshold at which PCI lost its mortality benefit was identified as 119.51 minutes (door-to-wiring time - door-to-needle time). Subgroup analyses showed that older patients, patients with anterior infarction, and those with a higher Killip class appeared to have lower equipoise thresholds.

Conclusions: Primary PCI offers a mortality benefit compared with O-FT in patients with timely treated ST-segment-elevation myocardial infarction, but treatment delays can mitigate this benefit. In settings with prolonged treatment delays, immediate fibrinolysis may be a more effective strategy. Treatment decisions should incorporate both patient characteristics and health care system constraints to optimize ST-segment-elevation myocardial infarction outcomes.

Keywords: comparative research; fibrinolysis; myocardial infarction; percutaneous coronary intervention; transfer.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • China / epidemiology
  • Female
  • Fibrinolytic Agents* / administration & dosage
  • Fibrinolytic Agents* / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention* / adverse effects
  • Percutaneous Coronary Intervention* / methods
  • Percutaneous Coronary Intervention* / mortality
  • Registries
  • ST Elevation Myocardial Infarction* / diagnosis
  • ST Elevation Myocardial Infarction* / mortality
  • ST Elevation Myocardial Infarction* / therapy
  • Thrombolytic Therapy* / adverse effects
  • Thrombolytic Therapy* / methods
  • Thrombolytic Therapy* / mortality
  • Time Factors
  • Time-to-Treatment
  • Treatment Outcome

Substances

  • Fibrinolytic Agents